caa a22 4500 469116226 CHVBK 20180323133125.0 cr unu---uuuuu 170328e19920101xx s 000 0 eng 10.1007/BF00172459 doi (NATIONALLICENCE)springer-10.1007/BF00172459 Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-α. Results of a phase I clinical trial [Elektronische Daten] [Randall Merchant, Daniel McVicar, Lynn Merchant, Harold Young] Summary: Nine patients with a recurrent malignant glioma were treated with repeated intracavitary or intracerebroventricular injections of human recombinant interleukin-2 (rIL-2) alone or in combination with systemic interferon-α (IFN-α). Five patients received only rIL-2 and four were treated with rIL-2 plus subcutaneous injections of IFN-α. Therapy was administered on a Monday, Wednesday, Friday schedule for up to 10 weeks, beginning with a dose of 10,000 IU rIL-2/injection. Doses were escalated every two weeks until some toxicity was apparent. The maximum amount of rIL-2 any one patient in this group received was 580,000 IU. Patients on combination immunotherapy were held at an rIL-2 dosage of 10,000 IU while IFN-α, which began at 3 million IU, was escalated every other week up to 18 million IU/dose. They were then held at that IFN-α dosage and rIL-2 was increased to 50,000 IU. The total amount of rIL-2 and IFN-α any one in this group received was 510,000IU and 417 million IU, respectively. Repeated injections of 10,000 IU rIL-2 were well-tolerated by all nine patients and no change in their functional status was seen. At doses at 50,000 IU. rIL-2, increased edema around the tumor cavity was observed by MRI/CT scand in 3/5 patients and clinical side-effects in the form of somnolence and headache along with some morbidity specifically associated with tumor location were also seen. Patients receiving rIL-2 + IFN-α showed progressive fatigue, muscle weakness, and occasionally nausea. Two of these patients showed increased peritumoral edema on MRI/CT scan. Neither hematological abnormalities nor changes from baseline values were seen in blood samples from any of the patients. MRI/CT scans made at the conclusion of immunotherapy indicated tumor progression in two of the patients treated with rIL-2 alone while no tumor growth at the site of treatment occurred in the other two or in the four treated with the combination of rIL-2 and IFN-α. Further clinical testing of rIL-2 in combination with IFN-α is indicated. Kluwer Academic Publishers, 1992 IL-2, roferon-A nationallicence toxicity nationallicence intracavitary nationallicence immunotherapy nationallicence cytokines nationallicence brain tumor nationallicence Merchant Randall Department of Surgery, Division of Neurosurgery, Virginia Commonwealth University, Richmond, Virginia, USA aut McVicar Daniel Department of Anatomy, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA aut Merchant Lynn Department of Surgery, Division of Neurosurgery, Virginia Commonwealth University, Richmond, Virginia, USA aut Young Harold Department of Surgery, Division of Neurosurgery, Virginia Commonwealth University, Richmond, Virginia, USA aut Journal of Neuro-Oncology Kluwer Academic Publishers 12/1(1992-01-01), 75-83 0167-594X 12:1<75 1992 12 11060 https://doi.org/10.1007/BF00172459 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00172459 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Merchant Randall Department of Surgery, Division of Neurosurgery, Virginia Commonwealth University, Richmond, Virginia, USA aut NATIONALLICENCE 700 1- McVicar Daniel Department of Anatomy, Medical College of Virginia, Virginia Commonwealth University, Richmond, Virginia, USA aut NATIONALLICENCE 700 1- Merchant Lynn Department of Surgery, Division of Neurosurgery, Virginia Commonwealth University, Richmond, Virginia, USA aut NATIONALLICENCE 700 1- Young Harold Department of Surgery, Division of Neurosurgery, Virginia Commonwealth University, Richmond, Virginia, USA aut NATIONALLICENCE 773 0- Journal of Neuro-Oncology Kluwer Academic Publishers 12/1(1992-01-01), 75-83 0167-594X 12:1<75 1992 12 11060 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer